Cure My Disease

Don't miss your cure!

 Log in / Sign up

New ultrasound technique could spare liver patients from costly scans and needles

NCT ID NCT00243633

Diagnosis Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether a special ultrasound with contrast dye (CEUS) can more accurately identify liver lesions than standard ultrasound or other imaging methods like CT and MRI. Researchers enrolled 878 participants with liver lesions found on standard ultrasound. The goal was to see if CEUS could provide a reliable diagnosis without needing invasive biopsies, potentially saving costs and discomfort.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Contrast-enhanced ultrasound (CEUS) imaging
What this could lead to
If successful, CEUS could become a standard, non-invasive way to accurately diagnose liver lesions, reducing the need for more expensive or invasive tests like CT, MRI, or biopsy.
What could go wrong
This is a completed study, so results are already known. The main risk is that CEUS may not be accurate enough for all types of liver lesions, and it cannot be used in patients with certain heart conditions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

878 people

The number who actually took part.

Start date

Apr 2005

Finished

Aug 2007

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Target focal liver lesion of size lower than 10 cm and higher than 5 mm detected by conventional ultrasonography Exclusion Criteria: * Patients with acute coronary syndrome or clinically unstable ischaemic cardiac disease, including: myocardial infarction, recent coronary artery intervention, acute cardiac failure (within last month), acute endocarditis and prosthetic valves. * Pregnant and lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Focal liver lesions are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis liver cancer Liver Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Focal liver lesions Liver cancer Liver cirrhosis

Contacts and locations

Locations

  • CHRU d'ANGERS

    Angers, 49033, France

  • Hospices Civils de Lyon

    Lyon, 69003, France

  • Hôpital Beaujon, Assistance Publique Hôpitaux de Paris

    Clichy, 92118, France

  • Hôpital Bretonneau, CHRU Tours

    Tours, 37044, France

  • Hôpital La Milétrie, CHRU Poitiers

    Poitiers, 86000, France

  • Hôpital Necker, Assistance Publique Hôpitaux de Paris

    Paris, 75743, France

  • Hôpital Nord, CHRU Saint-Etienne

    Saint-Etienne, 42055, France

  • Hôpital Paul Brousse, Assistance Publique Hôpitaux de Paris

    Villejuif, 94804, France

  • Hôpital Pitié Salpétrière, Assistance Publique Hôpitaux de Paris

    Paris, 75651, France

  • Hôpital Robert Debré, CHRU Reims

    Reims, 51092, France

  • Hôpital Saint-André, CHRU Bordeaux

    Bordeaux, 33075, France

  • Hôpital Saint-Eloi, CHRU Montpellier

    Montpellier, 34295, France

  • Hôpital Saint-Jacques, CHRU Besancon

    Besançon, 25000, France

  • Institut Gustave Roussy

    Villejuif, 94805, France

  • Service de Radiologie, Hôpital d'Enfants de Brabois

    Vandœuvre-lès-Nancy, 54511, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.